|Datasheet||Specific References||Reviews||Related Products||Protocols|
pMD18-T Simple Vector is a high-efficiency TA cloning vector constructed from pUC18, of which the initial multiple cloning sites (MCS) were destroyed. Thus the cDNA should be amplified by PCR with primers containing a restriction site for subclone. Competent cells appropriate for pUC18 are also appropriated for the Vector, e.g. JM109, DH5α, TOP10. The pMD18-T Simple Vector is 2.6kb in size. Selection of the plasmid in E. coli is conferred by the ampicillin resistance gene. The coding sequence was inserted by TA cloning at site 425.
The coding sequence can be amplified by PCR with M13-47 and RV-M primers.
|Human SFTPD ORF mammalian expression plasmid, C-GFPSpark tag||HG11041-ACG|
|Human SFTPD ORF mammalian expression plasmid, C-OFPSpark / RFP tag||HG11041-ACR|
|Human SFTPD ORF mammalian expression plasmid, C-Flag tag||HG11041-CF|
|Human SFTPD ORF mammalian expression plasmid, C-His tag||HG11041-CH|
|Human SFTPD ORF mammalian expression plasmid, C-Myc tag||HG11041-CM|
|Human SFTPD ORF mammalian expression plasmid, C-HA tag||HG11041-CY|
|Human SFTPD ORF mammalian expression plasmid, N-Flag tag||HG11041-NF|
|Human SFTPD ORF mammalian expression plasmid, N-His tag||HG11041-NH|
|Human SFTPD ORF mammalian expression plasmid, N-Myc tag||HG11041-NM|
|Human SFTPD ORF mammalian expression plasmid, N-HA tag||HG11041-NY|
|Human SFTPD natural ORF mammalian expression plasmid||HG11041-UT|
|Learn more about expression Vectors|
Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of C-type lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides it is involved in the development of acute and chronic inflammation of the lung. Several human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.